Title: Cosmetic or dermatological composition comprising a merocyanine and pentaery th rity I tetra-di-t-butyl hydroxyhydrocinnamate

[0001 ] The present invention relates to a cosmetic or dermatological composition comprising at least one merocyanine of formula (3) that will be defined below in detail and pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate.

[0002] The present invention also relates to a non-therapeutic cosmetic process for caring for and/or making up a keratin material, comprising the application, to the surface of said keratin material, of at least one composition according to the invention as defined above.

[0003] The invention also relates to a non-therapeutic cosmetic process for limiting the darkening of the skin and/or improving the colour and/or uniformity of the complexion, comprising the application, to the surface of the keratin material, of at least one composition as defined previously.

[0004] The invention also relates to a non-therapeutic cosmetic process for preventing and/or treating the signs of ageing of a keratin material, comprising the application, to the surface of the keratin material, of at least one composition as defined previously.

[0005] It is known that radiation with a wavelength of between 280 nm and 400 nm allows tanning of the human epidermis and that radiation with a wavelength of between 280 and 320 nm, known under the name UVB rays, harms the development of a natural tan. Exposure is also liable to induce impairment of the biomechanical properties of the epidermis, which is reflected by the appearance of wrinkles, leading to premature ageing of the skin.

[0006] It is also known that UVA rays with wavelengths of between 320 and 400 nm penetrate more deeply into the skin than UVB rays. UVA rays cause immediate and persistent browning of the skin. Daily exposure to UVA rays, even of short duration, under normal conditions can result in damage to the collagen fibres and the elastin, which is reflected by a modification of the microrelief of the skin, the appearance of wrinkles and uneven pigmentation (liver spots, heterogeneity of the complexion).

[0007] Protection against UVA and UVB radiation is therefore necessary. An effective photoprotective product must protect against both UVA and UVB radiation.

[0008] Many photoprotective compositions have been proposed to date to overcome the effects induced by UVA and/or UVB radiation. They generally contain organic UV-screening agents and/or inorganic UV-screening agents, which function according to their own chemical nature and according to their own properties by absorption, reflection or scattering of the UV radiation. They generally contain mixtures of liposoluble organic screening agents and/or of water-soluble UV-screening agents combined with metal oxide pigments such as titanium dioxide or zinc oxide.

[0009] Many cosmetic compositions intended to limit darkening of the skin, and to improve the colour and uniformity of the complexion have been proposed to date. It is well known in the field of antisun products that such compositions can be obtained by using UV-screening agents, and in particular UVB-screening agents. Some compositions may also contain UVA-screening agents. This screening system must cover UVB protection for the purpose of limiting and controlling the neosynthesis of melanin promoting overall pigmentation, but must also cover UVA protection in order to limit and control the oxidation of the already existing melanin resulting in darkening of the skin colour.

[0010] However, it is extremely difficult to find a composition containing a particular combination of UV-screening agents that would be specially suitable for photoprotection of the skin and particularly for an improvement in the quality of the skin both in terms of the colour and in terms of its mechanical elasticity properties.

[0011 ] Advantageously, this improvement is particularly desired on skin that is already pigmented, for the purpose of not increasing either the pigmentary melanin load or the structure of the melanin already present within the skin.

[0012] In fact, the majority of organic UV-screening agents consist of aromatic compounds which absorb in the wavelength range between 280 and 370 nm. In addition to their solar radiation-screening capacity, the desired photoprotective compounds must also have good cosmetic properties, good solubility in the usual solvents and in particular in fatty substances such as oils, or in water, and also good photostability alone or in combination with other UV-screening agents. They must also be colourless or at least have a colour that is cosmetically acceptable for consumers.

[0013] One of the main drawbacks known to date of these compositions is that these screening systems have insufficient efficiency against UV radiation and particularly against long UVA radiation with a wavelength above 370 nm with the aim of controlling light-induced pigmentation and the evolution thereof by means of a system which screens out UV radiation over the whole of the UV spectrum.

[0014] Among all the compounds that have been recommended for this purpose, an advantageous family of UV-screening agents which is constituted of carbonated merocyanine derivatives has been proposed, which is described in patent US 4 195 999, application WO 2004/006878 and document IP COM Journal 4 (4), 16 No. IPCOM000011179D published on 04/03/2004. These compounds have very good screening properties in the long UVA radiation range, but have poorly satisfactory solubility in the usual solvents, both in the aqueous phase and in the fatty phase, and an unsatisfactory photostability for some merocyanines.

[0015] With the aim of searching for other merocyanines which have better solubility in the usual solvents and better photostability, application WO 2013/011094 has proposed merocyanines comprising polar groups constituted of hydroxyl and ether functions, which show good long UVA-screening efficiency. However, the photostability of these particular merocyanines is still not entirely satisfactory, when it is used alone or in combination with other screening agents.

[0016] There thus remains the need to improve the photostability of these merocyanines in photoprotective formulations, whether they are dissolved in the aqueous phase and/or in the fatty phase, while still obtaining good cosmeticity.

[0017] The applicant has discovered, surprisingly, that by using pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, it was possible to substantially improve the photostability of these merocyanines in an aqueous phase as well as in a fatty phase. This discovery forms the basis of the present invention.

[0018] Therefore, in accordance with one of the subjects of the present invention, there is now proposed a cosmetic or dermatological composition comprising at least one merocyanine of formula (3) that will be defined below in detail and pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate. [0019] Moreover, there also remains the need to improve the photostability of merocyanines in the presence of organic screening agents such as dibenzoylmethane derivatives, for example. Indeed, the addition of additional screening agents, in particular dibenzoylmethane derivatives, can destabilize compositions comprising a merocyanine.

[0020] Dibenzoylmethane derivatives, and in particular 4-tert-butyl-4'- methoxydibenzoylmethane, constitute a family of particularly effective IIV-A screening agents having a high intrinsic absorption power. These dibenzoylmethane derivatives, which are now products well known per se as UV-A-active screening agents, are described in particular in the French patent applications FR-A-2326405 and FR-A- 2440933, and also in European patent application EP-A-0114607; 4-tert-butyl-4'- methoxydibenzoylmethane is in addition currently sold under the trade name "PARSOL 1789 ®" by DSM Nutritional Products.

[0021 ] However, it has been found that the combinations of merocyanine derivatives with dibenzoylmethane derivatives have the disadvantage of being particularly photo-unstable with respect to ultraviolet radiation (especially IIV-A). These particular combinations of UV screening agents degrade more or less rapidly under the effect of UV radiation; this degradation being particularly significant for merocyanine derivatives. Thus, this substantial lack of photochemical stability of the combination of merocyanine derivatives with dibenzoylmethane derivatives in the face of the ultraviolet radiation to which this combination is by nature intended to be subjected, does not make it possible to guarantee consistent protection during prolonged sun exposure, such that repeated applications at regular and close intervals of time have to be carried out by the user in order to obtain effective and lasting protection of the skin against UV rays.

[0022] There is therefore a real need to photostabilize the combination of merocyanine derivatives with dibenzoylmethane derivatives with respect to UV radiation in order to guarantee consistent protection during prolonged sun exposure with respect to UV-A radiation.

[0023] The applicant has discovered, surprisingly, that by using pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, it was possible to substantially improve the photostability of these merocyanines in an aqueous phase or in a fatty phase, even in the presence of additional organic UV-screening agents, in particular dibenzoylmethane derivatives.

[0024] The applicant has also discovered that the use of pentaerythrityl tetra- di-t-butyl hydroxyhydrocinnamate made it possible to obtain good cosmeticity of the composition comprising the merocyanines, said composition being in particular non- greasy and non-tacky.

[0025] The present invention also relates to a non-therapeutic cosmetic process for caring for and/or making up a keratin material, comprising the application, to the surface of said keratin material, of at least one composition according to the invention as defined above.

[0026] The invention also relates to a non-therapeutic cosmetic process for limiting the darkening of the skin and/or improving the colour and/or uniformity of the complexion, comprising the application, to the surface of the keratin material, of at least one composition as defined previously.

[0027] The invention also relates to a non-therapeutic cosmetic process for preventing and/or treating the signs of ageing of a keratin material, comprising the application, to the surface of the keratin material, of at least one composition as defined previously.

[0028] The present invention also relates to the use of pentaerythrityl tetra-d i-t- butyl hydroxyhydrocinnamate for photostabilizing a merocyanine of formula (3) as defined below, alone or in the presence of an additional screening agent, in particular in the presence of one or more dibenzoylmethane derivatives such as 4-tert-butyl-4'- methoxydibenzoylmethane.

[0029] Other characteristics, aspects and advantages of the invention will become apparent on reading the detailed description which follows.

[0030] The composition according to the invention is intended for topical application and thus contains a physiologically acceptable medium. The term “physiologically acceptable medium” means here a medium that is compatible with keratin materials.

[0031 ] In the context of the present invention, the term “keratin material” notably means the skin, the scalp, keratin fibres such as the eyelashes, the eyebrows, head hair, bodily hair, the nails, and mucous membranes such as the lips, and more particularly the skin and the mucous membranes (of the body, face, area around the eyes, eyelids, lips, preferably of the body, face and lips).

[0032] In the text which follows, unless otherwise indicated, the limits of a range of values are included in that range, notably in the expressions “between” and “ranging from ... to ...”.

[0033] Moreover, the expressions “at least one” and “at least” used in the present description are equivalent to the expressions “one or more” and “greater than or equal to”, respectively.

[0034] According to the invention, the term "preventing" or "prevention" is intended to mean reducing the risk of occurrence or slowing down the occurrence of a given phenomenon, namely, according to the present invention, the signs of ageing of a keratin material.

[0035] The expressions "optionally substituted" and "unsubstituted or substituted" are understood to mean that the radical or group may optionally be substituted by one or more hydroxy groups; amino groups -NR1 R2 such that R1 and R2 represent, independently of one another, hydrogen atoms or C1 -C3 alkyl radicals; carboxylic groups -COOH, carbonyl groups, or C1 -C4 alkyl groups.

MEROCYANINES

[0036] According to the present invention, use will be made of a family of merocyanines corresponding to formula (3) below, and also the geometric isomer forms, in particular the E/E or E/Z geometric isomer forms, thereof:

[Formula 3] in which:

A is -O- or -NH; R is a C1-C22 alkyl group, a C2-C22 alkenyl group, a C2-C22 alkynyl group, a C3-C22 cycloalkyl group or a C3-C22 cycloalkenyl group, said groups possibly being interrupted with one or more O.

[0037] The merocyanine compounds of the invention may be in the E/E- or E/Z geometric isomer forms thereof:

[formula 3]

[0038] The compounds of formula (3) that are even more preferential are those in which:

A is -O-; R is a C1-C22 alkyl, which may be interrupted with one or more O. [0039] Among the compounds of formula (3), use will be made more particularly of those chosen from the following group and also the geometric isomer forms, in particular the E/E or E/Z geometric isomer forms, thereof:

[Table 1 ]

[0040] According to a more particularly preferred embodiment of the invention, use will be made of the compound 2-ethoxyethyl (2Z)-cyano{3-[(3- methoxypropyl)amino]cyclohex-2-en-1 -ylidene}ethanoate (25) in its E/E and/or E/Z geometric configuration.

[0041 ] The E/Z form has the following structure:

[formula 25]

[0042] The E/E form has the following structure:

[formula 25a]

[0043] The screening merocyanines in accordance with the invention may be present in the compositions according to the invention in a concentration ranging from 0.1 % to 15% by weight, and preferentially from 0.2% to 10% by weight and even better still from 0.5% to 5% by weight relative to the total weight of the composition.

[0044] The compounds of formula (3), which form a carbocyclic ring containing 6 carbon atoms, may be prepared according to the protocols described in patent application WO 2007/071582, in IP.com Journal (2009), 9(5A), 29-30 IPCOM000182396D under the title “Process for producing 3-amino-2-cyclohexan-1 - ylidene compounds” and in US-A-4,749,643 on col. 13, line 66 - col. 14, line 57 and the references cited in this regard. [0045] In particular, the compounds of formula (3), such as the compound 2- ethoxyethyl (2Z)-cyano{3-[(3-methoxypropyl)am ino]cyclohex-2-en-1 - ylidenejethanoate (25), may be synthesized according to the synthesis scheme described in the publication from B. Winkler et al., Tetrahedron Letters, 55 (2014) 1749-1751 , entitled "A cyclic merocyanine IIV-A absorber: mechanism of formation and crystal structure" and represented below, for the compounds of formula (3): [formula 4]

And more particularly for compound 25 described in Table 1 : [formula 5]

PENTAERYTHRITYL TETRA-DI-T-BUTYL HYDROXYHYDROCINNAMATE

[0046] The composition according to the invention comprises pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate. [0047] Pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate is a compound that belongs to the family of cinnamic acids and derivatives thereof, having the CAS number 6683-19-8.

[0048] As an example, mention may be made of the pentaerythrityl tetra-di-t- butyl hydroxyhydrocinnamate compound sold by BASF under the name Tinogard TT®.

[0049] Preferably, a composition according to the invention comprises from 0.01 % to 2.5% by weight, preferably from 0.05% to 1 .5% by weight, more preferentially from 0.1 % to 0.3% by weight, of pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, relative to the total weight of the composition.

THE COMPOUNDS DERIVED FROM DIBENZOYLMETHANE

[0050] According to one particular embodiment, the composition according to the present invention further comprises one or more derivatives of dibenzoylmethane chosen from those of the following formula, and/or mixtures thereof:

[formula 6] in which:

Ri, R4, RS and Re represent, independently of one another, a hydrogen atom; a hydroxy radical; a linear or branched C1-C4 alkyl radical; or a linear or branched C1-C4 alkoxy radical; and

R2 and R3 represent, independently of one another, a hydrogen atom; a hydroxy radical; a linear or branched C1-C4 alkyl radical; a linear or branched C1-C4 alkoxy radical; or form, with the 2 carbon atoms of the covalent C-R2 and C-R3 bonds, a 5- or 6-membered heterocycle which is optionally substituted by a linear or branched C1-C4 hydrocarbon chain.

[0051 ] When R2 and R3 form a heterocycle with the 2 carbon atoms of the covalent C-R2 and C-R3 bonds, they preferably form a 5-membered aromatic heterocycle, more preferentially a furan ring. [0052] Preferably, R2 and R3 represent, independently of one another, a hydrogen atom; a hydroxy radical; a linear or branched C1-C4 alkyl radical; or a linear or branched C1-C4 alkoxy radical.

[0053] According to a preferred embodiment of the invention, the compound(s) derived from dibenzoylmethane are chosen, alone or as a mixture, from 2- methyldibenzoylmethane, 4-methyldibenzoylmethane, 4-isopropyldibenzoylmethane, 4-tert-butyldibenzoylmethane, 2,4-dimethyldibenzoylmethane, 2,5- dimethyldibenzoylmethane, 4,4'-diisopropyldibenzoylmethane, 4,4'- dimethoxydibenzoylmethane, 4-tert-butyl-4'-methoxydibenzoylmethane, 2-methyl-5- isopropyl-4'-methoxydibenzoylmethane, 2-methyl-5-tert-butyl-4'- methoxydibenzoylmethane, 2,4-dimethyl-4'-methoxydibenzoylmethane, 2,6-dimethyl- 4-tert-butyl-4'-methoxydibenzoylmethane, 1 -(4-tert-butylphenyl)-3-(2- hydroxyphenyl)propane-1 ,3-dione, 1 -(4-methoxy-1 -benzofuran-5-yl)-3- phenylpropane-1 ,3-dione; preferably chosen, alone or as a mixture, from 4-tert-butyl- 4'-methoxydibenzoylmethane and/or 4-isopropyldibenzoylmethane; preferentially chosen from 4-tert-butyl-4'-methoxydibenzoylmethane.

[0054] By way of example, 4-isopropyldibenzoylmethane is sold under the name "Eusolex 9020" by Merck, and 4-tert-butyl-4'-methoxydibenzoylmethane or Butyl Methoxydibenzoylmethane, of formula: [formula 7]

[0055] is sold under the name "PARSOL 1789" by DSM Nutritional Products.

[0056] Also by way of example, 1 -(4-methoxy-1 -benzofuran-5-yl)-3- phenylpropane-1 ,3-dione, of formula:

[formula 8] [0057] According to a particularly preferred embodiment, the composition according to the invention comprises 4-tert-butyl-4'-methoxydibenzoylmethane (INCI name: Butyl Methoxydibenzoylmethane).

[0058] When they are present, the content of the compound(s) derived from dibenzoylmethane is between 0.1 % and 15% by weight, preferably between 0.2% and 10% by weight, more preferentially between 0.3% and 5% by weight, relative to the total weight of the composition.

ADDITIONAL ACRYLIC POLYMER

[0059] According to a particular embodiment of the invention, the composition comprises at least one polymer comprising monomer units of formulae (A) and (B) defined below:

[formula A] [formula B] in which:

R1 , independently at each instance, is chosen from alkyl or alkenyl radicals, and at least 60% by weight of the Ri groups are radicals chosen from stearyl and behenyl radicals, the percentage by weight relating to the sum of all the Ri groups present in the polymer, and the weight ratio of the sum of all the hydroxyethyl acrylate units to the sum of all the acrylate units bearing the Ri group ranges from 1 :30 to 1 :1 , and the sum of the total of units A and B is at least 95% by weight relative to the total weight of the polymer. [0060] Preferably, Ri is constituted of alkyl radicals, preferably of C16-C22 alkyl radicals, and more preferentially of stearyl (Cis) radicals or of behenyl (C22) radicals.

[0061 ] Preferably, at least 70% by weight of the groups R1 are stearyl or behenyl radicals, preferentially at least 80% by weight and more preferentially at least 90% by weight.

[0062] According to a preferred embodiment, all the R1 groups are behenyl radicals.

[0063] According to another preferred embodiment, all the R1 groups are stearyl radicals.

[0064] Preferably, said weight ratio ranges from 1 :15 to 1 :1 and preferentially ranges from 1 :10 to 1 :4.

[0065] Advantageously, the polymer units present in the polymer consist of the units (A) and (B) previously described.

[0066] The polymer has a number-average molecular weight Mn ranging from 2000 to 9000 g/mol, preferably ranging from 5000 to 9000 g/mol. The number-average molecular weight may be measured via the gel permeation chromatography method, for example according to the method described in the example hereinbelow.

[0067] Preferably, the polymer has a melting point ranging from 40°C to 70°C and preferentially ranging from 45°C to 67°C. The melting point is measured by differential scanning calorimetry (DSC), for example according to the method described in the example hereinbelow.

[0068] According to a first embodiment, when the polymer is such that at least 60% by weight of the groups R1 are stearyl radicals, then the polymer preferably has a melting point ranging from 40 to 60°C, and preferentially ranging from 45 to 55°C.

[0069] According to a second embodiment, when the polymer is such that at least 60% by weight of the groups R1 are behenyl radicals, then the polymer has a melting point ranging from 60°C to 70°C, and preferentially ranging from 63°C to 67°C.

[0070] The polymer used according to the invention can be prepared by polymerization of a monomer of formula CH2=CH-C00-R-I, RI having the meaning previously described, and of 2-hydroxyethyl acrylate.

[0071 ] The polymerization may be performed according to known methods, such as solution polymerization or emulsion polymerization.

[0072] The polymerization is, for example, described in document US 2007/0264204.

[0073] The acrylic polymer(s) as defined previously can be present in the composition according to the invention in a content of active material ranging from 0.05% to 10% by weight, relative to the total weight of the composition, preferably ranging from 0.1 % to 5% by weight and better still ranging from 0.2% to 3% by weight.

FATTY PHASE

[0074] The composition in accordance with the invention may comprise at least one fatty phase.

[0075] For the purposes of the invention, the term "fatty phase" means a phase comprising at least one fatty substance, in particular a liquid, solid or pasty fatty substance, and all of the liposoluble and lipophilic ingredients used for the formulation of the compositions of the invention.

[0076] According to a particular embodiment, the composition according to the invention comprises at least one oil.

[0077] The term "oil" is intended to mean any fatty substance that is in liquid form at ambient temperature (20-25°C) and atmospheric pressure (760 mmHg).

[0078] The fatty phase may comprise, in particular, at least one volatile or nonvolatile hydrocarbon-based oil and/or one volatile and/or non-volatile silicone oil and/or one volatile and/or non-volatile fluoro oil.

[0079] For the purposes of the present invention, the term "silicone oil" is understood to mean an oil comprising at least one silicon atom, and in particular at least one Si-0 group.

[0080] The term "hydrocarbon-based oil" is intended to mean an oil mainly containing hydrogen and carbon atoms and optionally one or more heteroatoms, in particular nitrogen and oxygen. Thus, these oils may in particular contain one or more carboxy, ester, ether, hydroxyl functions.

[0081 ] The term "fluoro oil" is intended to mean an oil comprising at least one fluorine atom.

[0082] For the purposes of the invention, the term "volatile oil" is intended to mean an oil that is capable of evaporating on contact with the skin or the keratin fibre in less than one hour, at ambient temperature and atmospheric pressure. The volatile oil(s) of the invention are volatile cosmetic oils, which are liquid at ambient temperature, having a non-zero vapour pressure, at ambient temperature and atmospheric pressure, ranging in particular from 0.13 Pa to 40 000 Pa (10 ^-3 to 300 mmHg), in particular ranging from 1 .3 Pa to 13 000 Pa (0.01 to 100 mmHg) and more particularly ranging from 1.3 Pa to 1300 Pa (0.01 to 10 mmHg).

[0083] The term "non-volatile oil" is understood to mean an oil which remains on the skin or the keratin fibre, at ambient temperature and atmospheric pressure, for at least several hours and which has in particular a vapour pressure of less than 10’ ³ mmHg (0.13 Pa).

Hydrocarbon-based oils

[0084] The composition in accordance with the invention may comprise at least one ester of C2-C22 di- or tricarboxylic acid and of C1-C24 alcohols.

[0085] The C2-C22 di- or tricarboxylic acids are in particular chosen from citric acid, malic acid, malonic acid, succinic acid, adipic acid, maleic acid, fumaric acid, tartaric acid, isocitric acid, and mixtures thereof. The acids are preferably citric acid and adipic acid, and even more preferentially the acid is citric acid.

[0086] The C1-C24 alcohols are not oxyalkylenated. They may be aliphatic, cyclic or aromatic, having from 1 to 24 carbon atoms. They are in particular chosen from phenol, benzyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, methanol, ethanol, propanol, n-butanol, t-butanol, pentanol and hexanol. Preferably, the alcohol(s) is/are C1-C6 alcohol(s) and can be chosen from methanol, ethanol, propanol, n-butanol, t-butanol, pentanol, hexanol, and even more preferentially the alcohol is ethanol. [0087] The ester(s) of C2-C22 di- or tricarboxylic acid and of C1-C24 alcohols can be mono- or polyesterified.

[0088] Monoesterified is understood to mean that only one of the two or three carboxylic acid functions is esterified. Polyesterified is understood to mean that at least two carboxylic acid functions are esterified.

[0089] The di- or tricarboxylic acid can be esterified with a number of different alcohols. It is preferably esterified with just one alcohol.

[0090] According to a particular embodiment of the invention, the composition comprises at least one ester of C3-C22 tricarboxylic acid and of C1-C24, preferably Ci- Ce, alcohols. This/these ester(s) can be mono-, di- or triesterif ied.

[0091 ] Monoesterified is understood to mean that only one of the three carboxylic acid functions is esterified. Diesterified is understood to mean that two of the three carboxylic acid functions are esterified. Triesterified is understood to mean that all three carboxylic acid functions are esterified.

[0092] According to a particular embodiment of the invention, the ester(s) of C3- C22 tricarboxylic acid and of Ci-Ce alcohols are triesterified.

[0093] According to a particular embodiment of the invention, the ester(s) of C3- C22 tricarboxylic acid and of Ci-Ce alcohols are chosen from the compounds of formula (9) below:

(RIO-CO)CH2-C(R)(OC-OR2)-CH ₂ (OC-OR ₃ ) in which:

R1, R2 and R3 represent, independently of each other, a hydrogen atom or a monovalent, saturated or unsaturated, aliphatic, cyclic or aromatic hydrocarbon-based group having from 1 to 6 carbon atoms;

R represents a hydrogen atom or a hydroxyl radical.

[0094] According to a preferred embodiment, R1, R2 and R3 represent, independently of each other, a hydrogen atom or a linear or branched, substituted or unsubstituted, preferably unsubstituted, Ci-Ce alkyl radical, and in particular a radical chosen from methyl, ethyl, propyl, n-butyl, t-butyl, pentyl and hexyl radicals. Preferably, Ri , R2 and R3 are chosen, independently of each other, from a hydrogen atom and methyl, ethyl, propyl, n-butyl and t-butyl radicals.

[0095] According to a preferred embodiment of the invention, the radicals R1, R2 and R3 are identical and are chosen from C-i-Ce, preferably C1-C4, alkyl radicals and even more preferentially are ethyl radicals.

[0096] According to a preferred embodiment of the invention, R represents a hydroxyl radical.

[0097] According to a particular embodiment of the invention, the ester of tricarboxylic acid and of C-i-Ce alcohols has the following formula:

[Formula 10]

[0098] As an example of an ester of C3-C22 tricarboxylic acid and of C1 -C6 alcohols of formula (10) and having the INCI name TRIETHYL CITRATE, mention will be made of the product sold under the name CITROFOL Al EXTRA by Jungbunzlauer.

[0099] As non-volatile hydrocarbon-based oils that may be used according to the invention, mention may also be made of: hydrocarbon-based oils of plant origin, such as glyceride triesters, which are generally triesters of fatty acids and of glycerol, the fatty acids of which can have varied chain lengths from C4 to C24, it being possible for these chains to be saturated or unsaturated and linear or branched; these oils are in particular wheatgerm oil, sunflower oil, grape seed oil, sesame oil, com oil, apricot oil, castor oil, shea oil, avocado oil, olive oil, soybean oil, sweet almond oil, palm oil, rapeseed oil, cottonseed oil, hazelnut oil, macadamia oil, jojoba oil, alfalfa oil, poppy oil, pumpkin oil, marrow oil, blackcurrant oil, evening primrose oil, millet oil, barley oil, quinoa oil, rye oil, safflower oil, candlenut oil, passionflower oil and musk rose oil; or else caprylic/capric acid triglycerides, such as those sold by the company Stearineries Dubois or those sold under the names Miglyol 810®, 812® and 818® by the company Dynamit Nobel; synthetic ethers containing from 10 to 40 carbon atoms; linear or branched hydrocarbons of mineral or synthetic origin, such as petroleum jelly, polydecenes, hydrogenated polyisobutene, such as Parleam, squalane and mixtures thereof; synthetic esters, such as the oils of formula RCOOR' in which R represents a linear or branched fatty acid residue comprising from 1 to 40 carbon atoms and R' represents a hydrocarbon-based chain that is especially branched, containing from 1 to 40 carbon atoms, with the proviso that R + R' > 10, for instance Purcellin oil (cetostearyl octanoate), isopropyl myristate, isopropyl palmitate, C12-C15 alkyl benzoate, such as the product sold under the trade name Finsolv TN® or Witconol TN® by the company Witco or Tegosoft TN® by the company Evonik Goldschmidt, 2-ethylphenyl benzoate, such as the commercial product sold under the name X-Tend 226® by the company ISP, isopropyl lanolate, hexyl laurate, diisopropyl adipate, isononyl isononanoate, oleyl erucate, 2-ethylhexyl palmitate, isostearyl isostearate, di isopropyl sebacate such as the product sold under the name Dub Dis by the company Stearineries Dubois, alcohol or polyalcohol octanoates, decanoates or ricinoleates, such as propylene glycol dioctanoate; hydroxylated esters, such as isostearyl lactate, diisostearyl malate; and pentaerythritol esters; citrates or tartrates, such as linear C12-C13 dialkyl tartrates, such as those sold under the name Cosmacol ETI® by the company Enichem Augusta Industriale, and also linear C14-C15 dialkyl tartrates such as those sold under the name Cosmacol ETL® by the same company; acetates; fatty alcohols that are liquid at ambient temperature, containing a branched and/or unsaturated carbon-based chain containing from 12 to 26 carbon atoms, for instance octyldodecanol, isostearyl alcohol, oleyl alcohol, 2-hexyldecanol, 2-butyloctanol or 2- undecylpentadecanol;

C12-C22 higher fatty acids, such as oleic acid, linoleic acid or linolenic acid; carbonates, such as dicaprylyl carbonate, such as the product sold under the name Cetiol CC® by the company Cognis; and mixtures thereof. [0100] Among the non-volatile hydrocarbon-based oils that may be used according to the invention, preference will be given more particularly to glyceride triesters and in particular to caprylic/capric acid triglycerides, synthetic esters and in particular diisopropyl adipate, diisopropyl sebacate, isopropyl palmitate, dicaprylyl carbonate, isononyl isononanoate, oleyl erucate, C12-C15 alkyl benzoate, 2- ethylphenyl benzoate and fatty alcohols, in particular octyldodecanol. Preferably, the non-volatile hydrocarbon-based oils are chosen from diisopropyl adipate, diisopropyl sebacate, isopropyl palmitate and dicaprylyl carbonate.

[0101 ] As volatile hydrocarbon-based oils that may be used according to the invention, mention may be made in particular of hydrocarbon-based oils containing from 8 to 16 carbon atoms and in particular of branched Cs-C alkanes, such as Cs- C isoalkanes of petroleum origin (also known as isoparaffins), such as isododecane (also known as 2,2,4,4,6-pentamethylheptane), isodecane or isohexadecane, the oils sold under the Isopar or Permethyl trade names, branched Cs-C esters, isohexyl neopentanoate, and mixtures thereof.

[0102] Mention may also be made of the alkanes described in the Cognis patent applications WO 2007/068371 or WO 2008/155059 (mixtures of distinct alkanes differing by at least one carbon). These alkanes are obtained from fatty alcohols, which are themselves obtained from coconut kernel or palm oil. Mention may be made of the mixtures of n-undecane (C11) and n-tridecane (C13) obtained in Examples 1 and 2 of patent application WO 2008/155059 from the company Cognis. Mention may also be made of n-dodecane (C12) and n-tetradecane (C14) sold by Sasol under the respective references Parafol 12-97 and Parafol 14-97®, and also mixtures thereof.

[0103] Other volatile hydrocarbon-based oils, for instance petroleum distillates, in particular those sold under the name Shell Solt® by the company Shell, may also be used. According to one embodiment, the volatile solvent is chosen from volatile hydrocarbon-based oils containing from 8 to 16 carbon atoms, and mixtures thereof.

Silicone oils

[0104] The non-volatile silicone oils may be notably chosen from non-volatile polydimethylsiloxanes (PDMSs), polydimethylsiloxanes including alkyl or alkoxy groups which are pendent and/or at the end of the silicone chain, these groups each containing from 2 to 24 carbon atoms, or phenyl silicones, such as phenyl trimethicones, phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyl dimethicones, diphenylmethyldiphenyltrisiloxanes or 2-phenylethyl trimethylsiloxysilicates.

[0105] Examples of volatile silicone oils that may be mentioned include volatile linear or cyclic silicone oils, in particular those with a viscosity < 8 centistokes (8x1 O’ ⁶ m ² /s) and especially containing from 2 to 7 silicon atoms, these silicones optionally comprising alkyl or alkoxy groups containing from 1 to 10 carbon atoms. As volatile silicone oils that may be used in the invention, mention may notably be made of octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, heptamethylhexyltrisiloxane, heptamethyloctyltrisiloxane, hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane and dodecamethylpentasiloxane, and mixtures thereof.

[0106] A fatty phase according to the invention may also comprise other fatty substances, mixed with or dissolved in the oil.

[0107] Another fatty substance that may be present in the fatty phase may be, for example: a fatty acid chosen from fatty acids including from 8 to 30 carbon atoms, such as stearic acid, lauric acid, palmitic acid and oleic acid; a wax chosen from waxes such as lanolin, beeswax, carnauba or candelilla wax, rice bran wax, paraffin waxes, lignite waxes, microcrystalline waxes, ceresin or ozokerite, or synthetic waxes, such as polyethylene waxes or Fischer-Tropsch waxes; a gum chosen from silicone gums (dimethiconol); a pasty compound, such as polymeric or non-polymeric silicone compounds, esters of a glycerol oligomer, arachidyl propionate, fatty acid triglycerides and derivatives thereof; and mixtures thereof.

[0108] Preferentially, the overall fatty phase, including all the lipophilic substances other than the lipophilic screening agents of the composition capable of being dissolved in this same phase, represents from 5% to 95% by weight and preferentially from 10% to 80% by weight, relative to the total weight of the composition.

AQUEOUS PHASE

[0109] The composition in accordance with the invention may comprise at least one aqueous phase.

[0110] The aqueous phase contains water and optionally other water-soluble or water-miscible organic solvents.

[0111 ] An aqueous phase that is suitable for use in the invention may comprise, for example, a water chosen from a natural spring water, such as water from La Roche- Posay, water from Vittel, water from Saint Gervais Mont Blanc or waters from Vichy, or a floral water.

[0112] According to one particular form of the invention, the overall aqueous phase, including all the hydrophilic substances other than hydrophilic screening agents of the composition capable of being dissolved in this same phase, represents from 1 % to 99% by weight and preferentially from 10% to 80% by weight, relative to the total weight of the composition.

ADDITIVES

[0113] Additional UV-screeninq agents

[0114] The compositions according to the invention may also contain one or more additional UV-screening agents chosen from hydrophilic, lipophilic or insoluble organic UV-screening agents and/or one or more mineral pigments. It will preferentially be constituted of at least one hydrophilic, lipophilic or insoluble organic UV-screening agent.

[0115] The term "hydrophilic UV-screening agent" is intended to mean any cosmetic or dermatological organic or inorganic compound for screening out UV radiation, which can be fully dissolved in molecular form in a liquid aqueous phase or else which can be dissolved in colloidal form (for example in micellar form) in a liquid aqueous phase. [0116] The term "lipophilic screening agent" is intended to mean any cosmetic or dermatological organic or inorganic compound for screening out UV radiation, which can be fully dissolved in molecular form in a liquid fatty phase or else which can be dissolved in colloidal form (for example in micellar form) in a liquid fatty phase.

[0117] The term "insoluble UV-screening agent" is intended to mean any cosmetic or dermatological organic or inorganic compound for screening out UV radiation which has a solubility in water of less than 0.5% by weight and a solubility of less than 0.5% by weight in the majority of organic solvents such as liquid paraffin, fatty alcohol benzoates and fatty acid triglycerides, for example Miglyol 812® sold by the company Dynamit Nobel. This solubility, determined at 70°C, is defined as the amount of product in solution in the solvent at equilibrium with an excess of solid in suspension after returning to ambient temperature. It may be readily evaluated in the laboratory.

[0118] The additional organic UV-screening agents are chosen in particular from cinnamic compounds; anthranilate compounds; salicylic compounds; benzylidenecamphor compounds; benzophenone compounds; f3, [3-diphenylacrylate compounds; triazine compounds; benzotriazole compounds; benzalmalonate compounds, in particular those cited in patent US 5 624 663; benzimidazole derivatives; imidazoline compounds; bis-benzazolyl compounds, as described in patents EP 669 323 and US 2 463 264; p-aminobenzoic (PABA) compounds; methylenebis(hydroxyphenylbenzotriazole) compounds, as described in patent applications US 5 237 071 , US 5 166 355, GB 2 303 549, DE 197 26 184 and EP 893 119; benzoxazole compounds, as described in patent applications EP 0 832 642, EP 1 027 883, EP 1 300 137 and DE 101 62 844; screening polymers and screening silicones, such as those described in particular in patent application WO 93/04665; a- alkylstyrene-based dimers, such as those described in patent application DE 198 55 649; 4,4-diarylbutadiene compounds, as described in patent applications EP 0 967 200, DE 197 46 654, DE 197 55649, EP-A-1 008 586, EP 1 133 980 and EP 133 981 , and mixtures thereof.

[0119] As examples of organic photoprotective agents, mention may be made of those denoted hereinbelow under their INCI name.

[0120] Cinnamic compounds: Ethylhexyl methoxycinnamate sold in particular under the trade name Parsol MCX® by DSM Nutritional Products,

Isopropyl Methoxycinnamate,

Isoamyl p-Methoxycinnamate, sold under the trade name Neo Heliopan E 1000® by Symrise,

DEA Methoxycinnamate,

Diisopropyl Methylcinnamate,

Glyceryl Ethylhexanoate Dimethoxycinnamate.

[0121 ] para-Aminobenzoic compounds:

PABA,

Ethyl PABA,

Ethyl Dihydroxypropyl PABA,

Ethylhexyl Dimethyl PABA, sold in particular under the name Escalol 507® by ISP,

Glyceryl PABA,

PEG-25 PABA, sold under the name llvinul P 25® by BASF.

[0122] Salicylic compounds:

Homosalate, sold under the name Eusolex HMS® by Rona/EM Industries,

Ethylhexyl Salicylate, sold under the name Neo Heliopan OS® by Symrise, Dipropylene Glycol Salicylate, sold under the name Dipsal® by Scher, TEA Salicylate, sold under the name Neo Heliopan TS® by Symrise.

[0123] ft , ft -Diphenyl acrylate compounds:

Octocrylene, sold in particular under the trade name llvinul N 539® by BASF, Etocrylene, sold in particular under the trade name Uvinul N 35® by BASF.

[0124] Benzophenone compounds:

Benzophenone-1 , sold under the trade name Uvinul 400® by BASF,

Benzophenone-2, sold under the trade name Uvinul D 50® by BASF, Benzophenone-3 or Oxybenzone, sold under the trade name llvinul M 40® by BASF,

Benzophenone-4, sold under the trade name llvinul MS 40® by BASF,

Benzophenone-5,

Benzophenone-6, sold under the trade name Helisorb 11® by Norquay,

Benzophenone-8, sold under the trade name Spectra-Sorb UV-24® by American Cyanamid,

Benzophenone-9, sold under the trade name Uvinul DS 49® by BASF,

Benzophenone-12, n-Hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate, sold under the trade name Uvinul A Plus® or, as a mixture with octyl methoxycinnamate, under the trade name Uvinul A Plus B® by the company BASF,

1 , 1 '-(1 ,4-Piperazinediyl)bis[1 -[2-[4-(diethylamino)-2- hydroxybenzoyl]phenyl]methanone] (CAS 919803-06-8), as described in patent application WO 2007/071 584; this compound advantageously being used in micronized form (mean size of 0.02 to 2 pm), which may be obtained, for example, according to the micronization process described in patent applications GB-A-2 303 549 and EP-A-893 119, and in particular in the form of an aqueous dispersion.

[0125] Benzylidenecamphor compounds:

3-Benzylidene camphor, manufactured under the name Mexoryl SD® by Chimex,

4-Methylbenzylidene camphor, sold under the name Eusolex 6300® by Merck, Benzylidene Camphor Sulfonic Acid, manufactured under the name Mexoryl SL® by Chimex,

Camphor Benzalkonium Methosulfate, manufactured under the name Mexoryl SO® by Chimex,

Terephthalylidene Dicamphor Sulfonic Acid, manufactured under the name Mexoryl SX® by Chimex,

Polyacrylamidomethyl Benzylidene Camphor, manufactured under the name Mexoryl SW® by Chimex.

[0126] Phenylbenzimidazole compounds: Phenylbenzimidazole Sulfonic Acid, sold in particular under the trade name Eusolex 232® by Merck.

[0127] Bisbenzazolyl compounds:

Disodium Phenyl Dibenzimidazole Tetrasulfonate sold under the trade name Neo Heliopan AP® by Haarmann and Reimer.

[0128] Phenylbenzotriazole compounds:

Drometrizole Trisiloxane, sold under the name Silatrizole® by Rhodia Chimie.

[0129] Methylenebis(hydroxyphenylbenzotriazole) compounds:

Methylene bis-Benzotriazolyl Tetramethylbutylphenol, in particular in solid form, such as the product sold under the trade name Mixxim BB/100® by Fairmount Chemical, or in the form of an aqueous dispersion of micronized particles with a mean particle size ranging from 0.01 to 5 pm, more preferentially from 0.01 to 2 pm and more particularly from 0.020 to 2 pm, with at least one alkylpolyglycoside surfactant having the structure CnH2n+iO(CeHio05)xH, in which n is an integer from 8 to 16 and x is the mean degree of polymerization of the (CeH-ioOs) unit and ranges from 1.4 to 1.6, as described in patent GB-A-2 303549, sold in particular under the trade name Tinosorb M® by BASF, or in the form of an aqueous dispersion of micronized particles with a mean particle size ranging from 0.02 to 2 pm, more preferentially from 0.01 to 1.5 pm and more particularly from 0.02 to 1 pm, in the presence of at least one polyglyceryl mono(C8- C2o)alkyl ester with a degree of glycerol polymerization of at least 5, such as the aqueous dispersions described in patent application WO 2009/063392.

[0130] Triazine compounds:

3,3'-(1 ,4-Phenylene)bis(5,6-diphenyl-1 ,2,4-triazine), with the INCI name Phenylene bis-diphenyltriazine, and having the following chemical structure:

[formula 11]

Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, sold under the trade name Tinosorb S® by BASF,

Ethylhexyl Triazone sold in particular under the trade name llvinul T 150® by BASF,

Diethylhexyl Butamido Triazone, sold under the trade name Uvasorb HEB® by Sigma 3V,

2.4.6-tris(dineopentyl 4'-aminobenzalmalonate)-s-triazine,

2.4.6-tris(diisobutyl 4'-aminobenzalmalonate)-s-triazine,

2.4-bis(n-butyl 4'-aminobenzoate)-6-(aminopropyltrisiloxane)-s-triazine,

2.4-bis(dineopentyl 4'-aminobenzalmalonate)-6-(n-butyl 4'-aminobenzoate)-s-triazine, symmetrical triazine screening agents substituted with naphthalenyl groups or polyphenyl groups described in patent US 6 225 467, patent application WO 2004/085412 (see compounds 6 and 9) or the document "Symmetrical Triazine Derivatives", IP.COM IPCOM000031257 Journal, INC West Henrietta, NY, US (20 September 2004), in particular 2,4,6-tris(diphenyl)triazine and 2,4,6- tris(terphenyl)triazine, which is also mentioned in patent applications WO 06/035000, WO 06/034982, WO 06/034991 , WO 06/035007, WO 2006/034992 and WO 2006/034985, these compounds advantageously being used in micronized form (mean particle size of 0.02 to 3 pm), which may be obtained, for example, according to the micronization process described in patent applications GB-A-2 303549 and EP- A-893 119, and in particular in aqueous dispersion form, silicone triazines substituted with two aminobenzoate groups, as described in patent EP 0 841 341 , in particular 2,4-bis(n-butyl 4'-aminobenzalmalonate)-6-[(3-{1 ,3,3,3- tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl}propyl)amino] -s-triazine.

[0131 ] Anthranilic compounds: Menthyl anthranilate, sold under the trade name Neo Heliopan MA® by Symrise.

[0132] Imidazoline compounds:

Ethylhexyl Dimethoxybenzylidene Dioxoimidazoline Propionate.

[0133] Benzalmalonate compounds:

Polyorganosiloxane comprising benzalmalonate functions, such as Polysilicone-15, sold under the trade name Parsol SLX® by Hoffmann-La Roche.

[0134] 4,4-Diarylbutadiene compounds:

1 , 1 -Dicarboxy(2,2'-dimethylpropyl)-4,4-diphenylbutadiene.

[0135] Benzoxazole compounds:

2,4-Bis[5-(1-dimethylpropyl)benzoxazol-2-yl(4-phenyl)imin o]-6-(2-ethylhexyl)imino- 1 , 3, 5-triazine, sold under the name Uvasorb K2A® by Sigma 3V.

[0136] The preferential organic screening agents are chosen from:

Ethylhexyl Methoxycinnamate,

Ethylhexyl Salicylate,

Homosalate,

Octocrylene,

Phenylbenzimidazole Sulfonic Acid,

Benzophenone-3,

Benzophenone-4,

Benzophenone-5, n-Hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate,

4-Methylbenzylidene camphor,

Terephthalylidene Dicamphor Sulfonic Acid,

Disodium Phenyl Dibenzimidazole Tetrasulfonate,

Methylene bis-Benzotriazolyl Tetramethylbutylphenol,

Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine,

Ethylhexyl Triazone, Diethylhexyl Butamido Triazone,

2.4.6-Tris(dineopentyl 4'-aminobenzalmalonate)-s-triazine,

2.4.6-Tris(diisobutyl 4'-aminobenzalmalonate)-s-triazine,

2.4-Bis(n-butyl 4'-aminobenzoate)-6-(aminopropyltrisiloxane)-s-triazine,

2.4-Bis(dineopentyl 4'-aminobenzalmalonate)-6-(n-butyl 4'-aminobenzoate)-s- triazine,

2.4-Bis(n-butyl 4'-aminobenzalmalonate)-6-[(3-{1 ,3,3,3-tetramethyl-1 -

[(trimethylsilyl)oxy]disiloxanyl}propyl)amino]-s-triazine ,

2.4.6-Tris(diphenyl)triazine,

2.4.6-Tris(terphenyl)triazine,

Drometrizole Trisiloxane,

Polysilicone-15,

1 , 1 -Dicarboxy(2,2'-dimethylpropyl)-4,4-diphenylbutadiene,

2.4-Bis[5-(1-dimethylpropyl)benzoxazol-2-yl-(4-phenyl)imi no]-6-(2-ethylhexyl)imino- 1 ,3,5-triazine, and mixtures thereof.

[0137] The particularly preferred organic screening agents are chosen from:

Ethylhexyl Salicylate,

Homosalate,

Octocrylene, n-Hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate,

Terephthalylidene Dicamphor Sulfonic Acid,

Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine,

Ethylhexyl Triazone,

Diethylhexyl Butamido Triazone,

2.4-Bis(n-butyl 4'-aminobenzalmalonate)-6-[(3-{1 ,3,3,3-tetramethyl-1 -

[(trimethylsilyl)oxy]disiloxanyl}propyl)amino]-s-triazine , Drometrizole Trisiloxane, and mixtures thereof.

[0138] The inorganic UV-screening agents used in accordance with the present invention are metal oxide pigments. More preferentially, the inorganic UV-screening agents of the invention are metal oxide particles with a mean elementary particle size of less than or equal to 0.5 pm, more preferentially between 0.005 and 0.5 pm, even more preferentially between 0.01 and 0.2 pm, better still between 0.01 and 0.1 pm and more particularly between 0.015 and 0.05 pm.

[0139] They may be chosen in particular from titanium oxide, zinc oxide, iron oxide, zirconium oxide and cerium oxide, or mixtures thereof.

[0140] Such coated or uncoated metal oxide pigments are described in particular in patent application EP-A-0 518 773. Commercial pigments that may be mentioned include the products sold by the companies Sachtleben Pigments, Tayca, Merck and Degussa.

[0141 ] The metal oxide pigments may be coated or uncoated.

[0142] The coated pigments are pigments that have undergone one or more surface treatments of chemical, electronic, mechanochemical and/or mechanical nature with compounds such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron or aluminium salts of fatty acids, metal alkoxides (of titanium or aluminium), polyethylene, silicones, proteins (collagen, elastin), alkanolamines, silicon oxides, metal oxides or sodium hexametaphosphate.

[0143] The coated pigments are more particularly titanium oxides that have been coated: with silica, such as the product Sunveil® from the company Ikeda, with silica and iron oxide, such as the product Sunveil F® from the company Ikeda, with silica and alumina, such as the products Microtitanium Dioxide MT 500 SA® and Microtitanium Dioxide MT 100 SA from the company Tayca and Tioveil from the company Tioxide, with alumina, such as the products Tipaque TTO-55 (B)® and Tipaque TTO-55 (A)® from the company Ishihara and UVT 14/4 from the company Sachtleben Pigments, with alumina and aluminum stearate, such as the products Microtitanium Dioxide MT 100 T®, MT 100 TX®, MT 100 Z® and MT-01® from the company Tayca, the products Solaveil CT-10 W® and Solaveil CT 100® from the company Uniqema and the product Eusolex T-AVO® from the company Merck, with silica, alumina and alginic acid, such as the product MT-100 AQ® from the company Tayca, with alumina and aluminum laurate, such as the product Microtitanium Dioxide MT 100 S® from the company Tayca, with iron oxide and iron stearate, such as the product Microtitanium Dioxide MT 100 F® from the company Tayca, with zinc oxide and zinc stearate, such as the product BR 351® from the company Tayca, with silica and alumina and treated with a silicone, such as the products Microtitanium Dioxide MT 600 SAS®, Microtitanium Dioxide MT 500 SAS® or Microtitanium Dioxide MT 100 SAS® from the company Tayca, with silica, alumina and aluminum stearate and treated with a silicone, such as the product STT-30-DS® from the company Titan Kogyo, with silica and treated with a silicone, such as the product UV-Titan X 195® from the company Sachtleben Pigments, with alumina and treated with a silicone, such as the products Tipaque TTO-55 (S)® from the company Ishihara or UV Titan M 262® from the company Sachtleben Pigments, with triethanolamine, such as the product STT-65-S from the company Titan Kogyo, with stearic acid, such as the product Tipaque TTO-55 (C)® from the company Ishihara, with sodium hexametaphosphate, such as the product Microtitanium Dioxide MT 150 W® from the company Tayca, TiO2 treated with octyltrimethylsilane, sold under the trade name T 805® by the company Degussa Silices,

TiO2 treated with a polydimethylsiloxane, sold under the trade name 70250 Cardre UF TiO2SI3® by the company Cardre, anatase/rutile TiCh treated with a polydimethylhydrosiloxane, sold under the trade name Micro Titanium Dioxide USP Grade Hydrophobic® by the company Color Techniques,

TiO2 coated with triethylhexanoin, with aluminum stearate and with alumina sold under the trade name Solaveil CT-200-LQ-(WD) by Croda,

TiO2 coated with aluminum stearate, with alumina and with silicone sold under the trade name Solaveil CT-12W-LQ-(WD) by Croda,

TiO2 coated with lauroyl lysine sold by Daito Kasei Kogyo under the name LL 5 Titanium Dioxide CR 50,

TiO2 coated with C9-15 fluoroalcohol phosphate and with aluminum hydroxide sold by Daito Kasei Kogyo under the name PFX-5 TiO2 CR-50.

[0144] Mention may also be made of TiO2 pigments doped with at least one transition metal such as iron, zinc or manganese and more particularly manganese. Preferably, said doped pigments are in the form of an oily dispersion. The oil present in the oily dispersion is preferably chosen from triglycerides including those of capric/caprylic acids. The oily dispersion of titanium oxide particles may also comprise one or more dispersants, for instance a sorbitan ester, for instance sorbitan isostearate, or a polyoxyalkylenated fatty acid ester of glycerol, for instance TRI-PPG- 3 myristyl ether citrate and polyglyceryl-3 polyricinoleate. Preferably, the oily dispersion of titanium oxide particles includes at least one dispersant chosen from polyoxyalkylenated fatty acid esters of glycerol. Mention may be made more particularly of the oily dispersion of TiO2 particles doped with manganese in capric/caprylic acid triglyceride in the presence of TRI-PPG-3 myristyl ether citrate and polyglyceryl-3 polyricinoleate and sorbitan isostearate having the INCI name: titanium dioxide (and) TRI-PPG-3 myristyl ether citrate (and) polyglyceryl-3 ricinoleate (and) sorbitan isostearate, for instance the product sold under the trade name Optisol TD50® by the company Croda. [0145] The uncoated titanium oxide pigments are sold, for example, by the company Tayca under the trade names Microtitanium Dioxide MT 500 B or Microtitanium Dioxide MT 600 B®, by the company Degussa under the name P 25, by the company Wackher under the name Transparent titanium oxide PW®, by the company Miyoshi Kasei under the name LIFTR®, by the company Tomen under the name ITS® and by the company Tioxide under the name Tioveil AQ®.

[0146] The uncoated zinc oxide pigments are, for example: those sold under the name Z-Cote by the company Sunsmart; those sold under the name Nanox® by the company Elementis; those sold under the name Nanogard WCD 2025® by the company Nanophase Technologies.

[0147] The coated zinc oxide pigments are for example: those sold under the name Oxide Zinc CS-5® by the company Toshibi (ZnO coated with polymethylhydrosiloxane); those sold under the name Nanogard Zinc Oxide FN® by the company Nanophase Technologies (as a 40% dispersion in Finsolv TN®, C12-C15 alkyl benzoate); those sold under the name Daitopersion Zn-30® and Daitopersion Zn-50® by the company Daito (dispersions in cyclopolymethylsiloxane/oxyethylenated polydimethylsiloxane, containing 30% or 50% of zinc oxides coated with silica and polymethylhydrosiloxane); those sold under the name NFD Ultrafine ZnO® by the company Daikin (ZnO coated with perfluoroalkyl phosphate and copolymer based on perfluoroalkylethyl as a dispersion in cyclopentasiloxane); those sold under the name SPD-Z1® by the company Shin-Etsu (ZnO coated with silicone-grafted acrylic polymer, dispersed in cyclodimethylsiloxane); those sold under the name Escalol Z100® by the company ISP (alumina-treated ZnO dispersed in an ethylhexyl methoxycinnamate/PVP-hexadecene copolymer/methicone mixture); those sold under the name Fuji ZnO-SMS-10® by the company Fuji Pigment (ZnO coated with silica and polymethylsilsesquioxane); those sold under the name Nanox Gel TN® by the company Elementis (ZnO dispersed at 55% in C12-C15 alkyl benzoate with hydroxystearic acid polycondensate).

[0148] The uncoated cerium oxide pigments may be, for example, those sold under the name Colloidal Cerium Oxide® by the company Rhone-Poulenc.

[0149] The uncoated iron oxide pigments are sold, for example, by the company Arnaud under the names Nanogard WCD 2002® (FE 45B®), Nanogard Iron FE 45 BL AQ, Nanogard FE 45R AQ® and Nanogard WCD 2006® (FE 45R®) or by the company Mitsubishi under the name TY-220®.

[0150] The coated iron oxide pigments are sold, for example, by the company Arnaud under the names Nanogard WCD 2008 (FE 45B FN)®, Nanogard WCD 2009® (FE 45B 556®), Nanogard FE 45 BL 345® and Nanogard FE 45 BL® or by the company BASF under the name Transparent Iron Oxide®.

[0151 ] Mention may also be made of mixtures of metal oxides, especially of titanium dioxide and of cerium dioxide, including the equal-weight mixture of titanium dioxide and cerium dioxide coated with silica, sold by the company Ikeda under the name Sunveil A®, and also the mixture of titanium dioxide and zinc dioxide coated with alumina, silica and silicone, such as the product M 261® sold by the company Sachtleben Pigments, or coated with alumina, silica and glycerol, such as the product M 211® sold by the company Sachtleben Pigments.

[0152] According to the invention, coated or uncoated titanium oxide pigments are particularly preferred.

[0153] The additional UV-screening agents according to the invention can be present in the composition according to the invention in a content ranging from 0.1 % to 60% by weight and in particular from 5% to 30% by weight relative to the total weight of the composition.

Other additives

[0154] The composition in accordance with the present invention may also comprise conventional cosmetic adjuvants chosen in particular from organic solvents, ionic or non-ionic thickeners, softeners, humectants, opacifiers, stabilizers, emollients, silicones, antifoams, fragrances, preservatives, anionic, cationic, non-ionic, zwitterionic or amphoteric surfactants, active agents, fillers, polymers, propellants, basifying or acidifying agents or any other ingredient commonly used in the cosmetic and/or dermatological field.

[0155] Mention may be made, among organic solvents, of short-chain monoalcohols, for example C1-C4 monoalcohols such as ethanol and isopropanol, short-chain C2-C8 polyols, such as glycerol or diols, such as caprylyl glycol, 1 ,2- pentanediol, propanediol, butanediol, glycols and glycol ethers, such as ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol or diethylene glycol, 2-ethoxyethanol, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether, sorbitol, and mixtures thereof.

[0156] According to a preferred embodiment, use may be made more particularly of ethanol, propylene glycol, glycerol, and mixtures thereof.

[0157] Mention may be made, as thickeners, of carboxyvinyl polymers, such as the Carbopols® (Carbomers) and the Pemulens, such as Pemulen TR1® and Pemulen TR2® (acrylate/C10-C30 alkyl acrylate copolymer); polyacrylamides, for instance the crosslinked copolymers sold under the names Sepigel 305® (CTFA name: polyacrylamide/Ci3-i4 isoparaffin/Laureth 7) or Simulgel 600 (CTFA name: acrylamide/sodium acryloyldimethyl taurate copolymer/isohexadecane/polysorbate 80) by the company SEPPIC; 2-acrylamido-2-methylpropanesulfonic acid polymers and copolymers, optionally crosslinked and/or neutralized, such as the poly(2- acrylamido-2-methylpropanesulfonic acid) sold by the company Hoechst under the trade name Hostacerin AMPS® (CTFA name: ammonium polyacryloyldimethyl taurate) or Simulgel 800®, sold by the company SEPPIC (CTFA name: sodium polyacryloyldimethyl taurate/polysorbate 80/sorbitan oleate); copolymers of 2- acrylamido-2-methylpropanesulfonic acid and of hydroxyethyl acrylate, such as Simulgel NS® and Sepinov EMT 10®, sold by the company SEPPIC; cellulose derivatives, such as hydroxyethylcellulose; polysaccharides and in particular gums, such as xanthan gum; water-soluble or water-dispersible silicone derivatives, such as acrylic silicones, polyether silicones and cationic silicones, and mixtures thereof.

[0158] Among the acidifying agents, examples that may be mentioned include mineral or organic acids, for instance hydrochloric acid, orthophosphoric acid, sulfuric acid, carboxylic acids, for instance acetic acid, tartaric acid, citric acid or lactic acid, and sulfonic acids.

[0159] Among the basifying agents, examples that may be mentioned include aqueous ammonia, alkali metal carbonates, alkanolamines, such as mono-, di- and triethanolamines and derivatives thereof, sodium hydroxide or potassium hydroxide.

[0160] Preferably, the cosmetic composition comprises one or more basifying agents chosen from alkanolamines, in particular triethanolamine, and sodium hydroxide.

[0161 ] Among the active agents for caring for keratin materials such as the skin, the lips, the scalp, the hair, the eyelashes or the nails, mention may be made for example of vitamins and derivatives or precursors thereof, alone or as mixtures; antioxidants; free-radical scavengers; anti-pollutants; self-tanning agents; antiglycation agents; calmatives; deodorant agents; essential oils; NO-synthase inhibitors; agents for stimulating the synthesis of dermal or epidermal macromolecules and/or for preventing degradation thereof; agents for stimulating fibroblast proliferation; agents for stimulating keratinocyte proliferation; muscle relaxants; refreshing agents; tensioning agents; mattifying agents; depigmenting agents; propigmenting agents; keratolytic agents; desquamating agents; moisturizing agents; anti-inflammatories; antimicrobials; thinning agents; agents which act on cell energy metabolism; insect repellents; substance P antagonists or CRGP antagonists; agents for preventing hair loss; antiwrinkle agents; anti-ageing agents.

[0162] Those skilled in the art will select said active agent(s) as a function of the effect desired on the skin, the hair, the eyelashes, the eyebrows and the nails.

[0163] Needless to say, those skilled in the art will take care to select the optional additional compound(s) mentioned above and/or the amounts thereof such that the advantageous properties intrinsically associated with the compositions in accordance with the invention are not, or are not substantially, adversely affected by the envisioned addition(s).

PRESENTATION FORMS [0164] The compositions according to the invention may be aqueous or anhydrous.

[0165] When the compositions are aqueous, they contain at least one aqueous phase.

[0166] They may then be provided in purely aqueous form, that is to say that they comprise an amount of fatty phase of less than 10% by weight, preferably of less than 5% by weight, and more preferentially still of less than 2% by weight, relative to the total weight of the composition. Advantageously, the composition according to the invention is essentially aqueous, that is to say that it is devoid of fatty phase.

[0167] The compositions according to the invention may also be in the form of a simple or complex emulsion (O/W, W/O, O/W/O or W/O/W), such as a cream, a milk or a cream gel.

[0168] In the case where the composition in accordance with the invention is aqueous and it is possible to measure its pH, the pH is generally between 3 and 12 approximately, preferably between 5 and 9 approximately, and even more particularly from 5.5 to 8.

[0169] The compositions may also be in anhydrous form, for instance in the form of an oil, a glycolic solution or an alcoholic solution. The term "anhydrous composition" is intended to mean a composition containing less than 1 % by weight of water, or even less than 0.5% water, and especially free of water, the water not being added during the preparation of the composition but corresponding to the residual water provided by the mixed ingredients. They may optionally be packaged in aerosol form and may be in the form of a mousse or a spray.

[0170] In the case of compositions in the form of oil-in-water or water-in-oil emulsions, the emulsification processes that may be used are of the paddle or impeller, rotor-stator and HPH type.

[0171 ] In order to obtain stable emulsions with a low content of polymer (oil/polymer ratio > 25), it is possible to prepare the dispersion in concentrated phase and then to dilute the dispersion with the remainder of the aqueous phase.

[0172] It is also possible, via HPH (between 50 and 800 bar), to obtain stable dispersions with drop sizes that may be as small as 100 nm. [0173] The emulsions generally contain at least one emulsifier chosen from amphoteric, anionic, cationic or non-ionic emulsifiers, used alone or as a mixture. The emulsifiers are chosen in an appropriate manner according to the emulsion to be obtained (W/O or O/W emulsion).

[0174] Examples of W/O emulsifying surfactants that may be mentioned include alkyl esters or ethers of sorbitan, of glycerol, of polyol, of glycerol or of sugars; silicone surfactants, for instance dimethicone copolyols, such as the mixture of cyclomethicone and of dimethicone copolyol, sold under the name DC 5225 C® by the company Dow Coming, and alkyldimethicone copolyols such as laurylmethicone copolyol sold under the name Dow Corning 5200 Formulation Aid by the company Dow Coming; cetyldimethicone copolyol, such as the product sold under the name Abil EM 90R® by the company Goldschmidt, and the mixture of cetyldimethicone copolyol, of polyglyceryl isostearate (4 mol) and of hexyl laurate, sold under the name Abil WE 09® by the company Goldschmidt. One or more coemulsifiers, which may be chosen advantageously from the group comprising polyol alkyl esters, may also be added thereto.

[0175] Mention may also be made of non-silicone emulsifying surfactants, in particular alkyl esters or ethers of sorbitan, of glycerol, of polyol or of sugars.

[0176] Polyol alkyl esters that may in particular be mentioned include polyethylene glycol esters, for instance PEG-30 dipolyhydroxystearate, such as the product sold under the name Arlacel P135® by the company ICI.

[0177] Examples of glycerol and/or sorbitan esters that may be mentioned include polyglyceryl isostearate, such as the product sold under the name Isolan Gl 34® by the company Goldschmidt; sorbitan isostearate, such as the product sold under the name Arlacel 987® by the company ICI; sorbitan glyceryl isostearate, such as the product sold under the name Arlacel 986® by the company ICI, and mixtures thereof.

[0178] For the O/W emulsions, examples of non-ionic emulsifying surfactants that may be mentioned include polyoxyalkylenated (more particularly polyoxyethylenated and/or polyoxypropylenated) esters of fatty acids and of glycerol; oxyalkylenated esters of fatty acids and of sorbitan; polyoxyalkylenated (in particular polyoxyethylenated and/or polyoxypropylenated) esters of fatty acids, optionally in combination with an ester of a fatty acid and of glycerol, such as the PEG-100 stearate/glyceryl stearate mixture sold, for example, by the company ICI under the name Arlacel 165; oxyalkylenated (oxyethylenated and/or oxypropylenated) ethers of fatty alcohols; esters of sugars, such as sucrose stearate; or ethers of fatty alcohol and of sugar, in particular alkyl polyglucosides (APGs), such as decyl glucoside and lauryl glucoside, sold, for example, by the company Henkel under the respective names Plantaren 2000® and Plantaren 1200®, cetostearyl glucoside, optionally as a mixture with cetostearyl alcohol, sold, for example, under the name Montanov 68® by the company SEPPIC, under the name Tegocare CG90® by the company Goldschmidt and under the name Emulgade KE3302® by the company Henkel, and arachidyl glucoside, for example in the form of the mixture of arachidyl and behenyl alcohols and of arachidyl glucoside sold under the name Montanov 202® by the company SEPPIC. According to one particular embodiment of the invention, the mixture of the alkyl polyglucoside as defined above with the corresponding fatty alcohol may be in the form of a self-emulsifying composition, for example as described in the document WO-A-92/06778.

[0179] When it is an emulsion, the aqueous phase of this emulsion may comprise a non-ionic vesicular dispersion prepared according to known processes (Bangham, Standish and Watkins, J. Mol. Biol. 13, 238 (1965), FR 2 315 991 and FR 2 416 008).

[0180] The compositions according to the invention find their application in a large number of treatments, in particular cosmetic treatments, for the skin, the lips and the hair, including the scalp, in particular for protecting and/or caring for the skin, the lips and/or the hair, and/or for making up the skin and/or the lips.

[0181 ] Another subject of the present invention is constituted of the use of the compositions according to the invention as defined above for the manufacture of products for the cosmetic treatment of the skin, the lips, the nails, the hair, the eyelashes, the eyebrows and/or the scalp, in particular care products, antisun products and makeup products.

[0182] The cosmetic compositions according to the invention may be used, for example, as a makeup product.

[0183] Another subject of the present invention is constituted of a non- therapeutic cosmetic process for caring for and/or making up a keratin material, which consists in applying, to the surface of said keratin material, at least one composition according to the invention as defined above.

[0184] Another subject of the invention consists of the use of pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate to photostabilize a merocyanine of formula (3) as defined above.

[0185] Another subject of the invention consists of the use of pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate to photostabilize a merocyanine of formula (3) as defined above in the presence of one or more dibenzoylmethane derivatives, preferably in the presence of 4-(tert-butyl)-4'-methoxydibenzoylmethane.

[0186] The cosmetic compositions according to the invention may be used, for example, as a care product and/or antisun product for the face and/or body, with a liquid to semi-liquid consistency, such as milks, more or less smooth creams, cream gels or pastes. They may optionally be packaged in aerosol form and may be in the form of a mousse or a spray.

[0187] The compositions according to the invention in the form of vaporizable fluid lotions in accordance with the invention are applied to the skin or hair in the form of fine particles by means of pressurizing devices. The devices in accordance with the invention are well known to those skilled in the art and comprise non-aerosol pumps or "atomizers", aerosol containers comprising a propellant and aerosol pumps using compressed air as propellant. These devices are described in patents US 4 077 441 and US 4 850 517.

[0188] The compositions packaged in aerosol form in accordance with the invention generally contain conventional propellants, for instance hydrofluoro compounds, dichlorodifluoromethane, difluoroethane, dimethyl ether, isobutane, n- butane, propane or trichlorofluoromethane. They are preferably present in amounts ranging from 15% to 50% by weight relative to the total weight of the composition.

ASSEMBLY

[0189] According to another aspect, the invention also relates to a cosmetic assembly comprising: a container delimiting one or more compartments, said container being closed by a closing member and optionally being unsealed; and a makeup and/or care composition in accordance with the invention placed inside said compartment(s).

[0190] The container may be, for example, in the form of a jar or a box.

[0191 ] The closing member may be in the form of a lid comprising a cap mounted so as to be able to move by translation or by pivoting relative to the container housing said makeup and/or care composition(s).

EXAMPLES

[0192] The examples that follow serve to illustrate the invention without, however, being limiting in nature.

[0193] Example A1 : Preparation of compound (14)

[formula 14]

[0194] 122.23 grams of 3-[(3-methoxypropyl)amino]-2-cyclohexen-1-one are alkylated with dimethyl sulfate or alternatively with diethyl sulfate and treated with 75.45 grams of ethyl cyanoacetate in approximately equimolar proportions in the presence of a base and optionally of a solvent.

[0195] The base/solvent combinations indicated in the following table are used.

[Table 2]

[0196] The completion of the alkylation reaction can be monitored for example by methods such as TLC, GC or HPLC.

[0197] 162.30 grams of compound (14) are obtained in the form of a brown oil. [0198] After crystallization, the product is obtained in the form of yellowish crystals.

[0199] Melting point: 92.7°C.

[0200] Example A2: Preparation of compound (15) [formula 15]

[0201] 101.00 grams of 3-[(3-methoxypropyl)amino]-2-cyclohexen-1-one are alkylated with dimethyl sulfate or alternatively with diethyl sulfate and treated with 86.00 grams of 2-cyano-N-(3-methoxypropyl)acetamide in approximately equimolar proportions in the presence of a base and optionally of a solvent.

[0202] The base/solvent combinations indicated in the following table are used.

[Table 3] [0203] The crude product (15) is obtained in the form of a dark brown oil.

[0204] After silica gel column chromatography (eluent: 99/1 toluene/methanol), 81 .8 grams of product are obtained in the form of yellowish crystals.

[0205] Melting point: 84.7-85.3°C.

[0206] Example A3: Preparation of compound (27)

[formula 27]

[0207] 13.09 grams of 3-[(3-methoxypropyl)amino]-2-cyclohexen-1-one are alkylated with dimethyl sulfate or alternatively with diethyl sulfate and treated with 10.12 grams of isobutyl cyanoacetate in the presence of a base and optionally of a solvent.

[0208] The base/solvent combinations indicated in the following table are used.

[Table 4]

[0209] 15.97 grams of crude product (27) are obtained in the form of a dark brown oil.

[0210] After silica gel column chromatography (eluent: toluene/acetone), 13.46 grams of product are obtained in the form of yellowish crystals.

[0211] Melting point: 96.3°C. [0212] Example A4: Preparation of compound (25)

[formula 25]

[0213] 148.4 grams of 3-[(3-methoxypropyl)amino]-2-cyclohexen-1-one are alkylated with dimethyl sulfate or alternatively with diethyl sulfate and treated with 130.00 grams of 2-ethoxyethyl cyanoacetate in the presence of an organic base and of a solvent.

[0214] The base/solvent combinations indicated in the table below are used.

[Table 5]

[0215] Example of preparation of acrylic polymers:

[0216] Determination of the molecular weight by gel permeation chromatography (GPC):

[0217] The sample is prepared by preparing a solution of the polymer at 10 mg/ml in tetrahydrofuran. The sample is placed in an oven at 54°C for 10 minutes and then in an oscillating shaker for 60 minutes to aid dissolution. After visual inspection, the sample appears to be totally dissolved in the solvent.

[0218] The sample prepared was analysed using two polypore 300x7.5 mm columns (manufactured by Agilent Technologies), a Waters 2695 chromatographic system, a tetrahydrofuran mobile phase and detection by refractive index. The sample was filtered through a 0.45 pm nylon filter, before being injected into the liquid chromatograph. The standards used for the calibration are the Easi Vial narrow polystyrene (PS) standards from Agilent Technologies.

[0219] Polystyrene standards ranging from 2 520 000 to 162 daltons were used for the calibration.

[0220] The system is equipped with a PSS SECcurity 1260 Rl detector. The polystyrene calibration curve was used to determine the average molecular weight. The recording of the diagrams and the determination of the various molecular weights were performed by the Win GPC Unichrom 81 program.

[0221 ] Determination of the melting point by differential scanning calorimetry (or

DSC):

[0222] This method describes the general procedure for determining the melting point of polymers by differential scanning calorimetry. This method is based on the standards ASTM E791 and ASTM D 34182 and the DSC calibration is performed according to standard ASTM E 9672.

[0223] Behenyl acrylate/2-hvdroxyethyl acrylate copolymer (Polymer 1 ):

[0224] In a 4-necked flask equipped with a side-blade mixer, an internal thermometer, two funnels, a reflux condenser, and an extension for two other necks, 175 g of behenyl acrylate, 25 g of 2-hydroxyethyl acrylate and 0.4 g of 2,2'-azobis(2- methylbutyronitrile) (Akzo Nobel) were added, over the course of 60 minutes at 80°C, to 40 g of isopropanol, with stirring, after having removed the oxygen from the system by means of a nitrogen flush for 20 minutes. The mixture was stirred at 80°C for 3 hours. The solvent was then removed by vacuum distillation, 1 g of dilauryl peroxide was then added and the reaction was continued for 60 minutes at 110°C. The step was repeated. The mixture was then cooled to 90°C, a stream of demineralized water was added and the mixture was then stirred. The water was removed by vacuum distillation.

[0225] Molecular weight: Mn = 7300 g/mol, Mw = 21 000, Mw/Mn = 2.8

[0226] Melting point: 65°C [0227] Stearyl acrylate/2-hvdroxyethyl acrylate copolymer (Polymer 2):

[0228] In a 4-necked flask equipped with a side-blade mixer, an internal thermometer, two funnels, a reflux condenser, and an extension for two other necks, 155 g of stearyl acrylate, 45 g of 2-hydroxyethyl acrylate and 0.4 g of 2,2'-azobis(2- methylbutyronitrile) (Akzo Nobel) were added, over the course of 90 minutes at 80°C, to 50 g of isopropanol, with stirring, after having removed the oxygen from the system by means of a nitrogen flush for 20 minutes. The mixture was stirred at 80°C for 3 hours. The solvent was then removed by vacuum distillation, 1 g of dilauryl peroxide was then added and the reaction was continued for 60 minutes at 125°C. The step was repeated. The mixture was then cooled to 90°C, a stream of demineralized water was added and the mixture was then stirred. The water was removed by vacuum distillation.

[0229] Molecular weight: Mn = 7500 g/mol, Mw = 19 000, Mw/Mn = 2.6

[0230] Melting point: 49°C

[0231 ] Formulation examples

[0232] Comparative Examples 1 and 2

[0233] Compositions 1 and 2 are prepared from the ingredients indicated in the table below, the amounts of which are expressed in % by weight of starting material (SM) relative to the total weight of the composition.

[Table 6]

[0234] Method for preparing the compositions:

[0235] Phase A1 is prepared by mixing all of the ingredients, and then phase A2 is added for neutralization and gel formation. This is followed by addition of phase A3. All of this preparation of the phase, which will be referred to as A hereinafter, is carried out while heating to 65°C and with stirring with blades (50 rpm).

[0236] Phase B is prepared by mixing all of the ingredients while heating to 80°C with magnetic stirring until a clear and homogeneous phase is obtained.

[0237] Emulsification is carried out by dispersing phase B in phase A at 65°C and with intense stirring (blades at 80 rpm and turbine at 11 000 rpm) for 5 minutes. An oil-in-water emulsion is obtained. The temperature of the mixture is then reduced gradually to return to ambient temperature, while maintaining the same level of stirring until the end. At around 55°C, the thickeners of phase C are added (5 minutes), and then phase D (5 minutes) and the fillers of phase E starting from 35°C. Lastly, the alcohol of phase F is added once the mixture has returned to ambient temperature.

[0238] Results:

[0239] Once prepared, Compositions 1 and 2 are each spread over 6 Europlast brand PMMA plates at a rate of 2.0 to 2.1 mg/cm ² (which corresponds to between 16 and 17 mg over 8 cm ² ). 3 of the 6 plates are then exposed in a Suntest (Heraeus) with a UV dose of 43.2 J/cm ² at a temperature of 40°C, while the others are stored at the same temperature in the dark.

[0240] After irradiation, the residual contents of 2-ethoxyethyl 2-cyano{3-[(3- methoxypropyl)amino]cyclohex-2-en-1-ylidene}ethanoate in each of the 6 plates are measured by conventional HPLC chromatography methods. [0241 ] The residual fraction after irradiation expressed in % corresponds to the ratio of the average of the residual contents of the ingredient contained on the 3 plates that had been exposed in relation to the average of the residual contents of the 3 plates that had not been exposed, for a given composition. [0242] The results obtained are collated in the table below.

[Table 7]

[0243] These results show that Composition 2 according to the invention exhibits a residual fraction of merocyanine compound that is substantially greater than that of Comparative Composition 1 , which shows that, in the presence of pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, the merocyanine compound exhibits better photostability with respect to UV radiation.